Memory support neighborhood takes ‘dignified approach’ to dementia care … Bias in test of lung function leaves up to 40% of Black males undiagnosed … FDA revokes EUA for J&J’s COVID vaccine...
COVID-19 may be a new risk factor for chronic pain, national study finds
By
Alicia Lasek
Jun 30, 2023
Fully 26% of study participants with moderate to severe COVID-19 symptoms reported frequent pain, researchers report.
FDA advisers object to Alzheimer’s drug aducanumab ahead of final decision
By
Alicia Lasek
Apr 05, 2021
The experimental Alzheimer’s drug aducanumab is not ready for federal approval in June, advisers to the Food and Drug Administration say in a new JAMA editorial.
After 20 years on the market, AbbVie’s dry-eye drug Restasis to be available as generic
By
Alicia Lasek
Feb 03, 2022
Dry eyes affect nearly 19% percent of adults aged 75 years and older, according to data from a national survey.
Feds struggle to provide COVID-19 tally for nursing homes: report
By
Alicia Lasek
May 09, 2020
Weeks after CMS announced it would begin tracking outbreaks and deaths in the nation’s eldercare facilities, there are no solid numbers available, say investigators.
25 percent of COVID patients have post-acute symptoms; Report highlights emerging care needs
By
Alicia Lasek
Jun 18, 2021
A analysis based on nearly two million private U.S. healthcare claims has identified the most common post-COVID conditions with a focus on age, gender, mental health conditions and mortality. Even 19%...
Most senior living facilities short on coronavirus-fighting supplies, survey finds
By
Alicia Lasek
Mar 17, 2020
More than two-thirds of the nation’s senior living facilities report trouble sourcing equipment, particularly N95 respirators.
HHS sets national plan to ‘end cancer as we know it’
By
Alicia Lasek
Apr 04, 2023
A new framework sets goals for early detection and prevention; development of effective treatments; eliminating cancer-care related inequalities; and supporting optimal care delivery.
Feds identify promising and ‘urgently needed’ COVID antiviral drug
By
Alicia Lasek
Jun 04, 2021
The experimental drug TEMPOL has shown promise in early studies, halting the activity of a viral enzyme and limiting the severity of SARS-CoV-2 infections.
Remdesivir effective against COVID-19, researchers conclude
By
Alicia Lasek
Oct 13, 2020
Intravenous remdesivir shortens recovery time and reduces mortality in hospitalized patients when compared to placebo, according to final trial data from NIAID. No other antiviral has yet been confirmed...